Supply Chain Intelligence

Kyntra Bio, Inc. Supply Chain

KYNB supply chain intelligence for Kyntra Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

KYNB ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
3Customers
2Debt Items
20Related Chains

Kyntra Bio, Inc. Suppliers

TickerNameConfidenceEvidence
NOVAQUEST NOVAQUEST 92% Company entered into a Revenue Interest Financing Agreement (the “RIFA”) with an affiliate of NovaQuest Capital Management ("NovaQuest"), pursuant to which the Company granted NovaQuest 22.5 % of its…
AZN AstraZeneca PLC 72% straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, our revenue for continuing operations was substantially related to our collaboratio…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, ou…

Kyntra Bio, Inc. Customers

TickerNameConfidenceEvidence
FALIKANG FALIKANG 90% Our proportionate share of the reported profits or losses of Falikang, was included in the discontinued operations in the condensed consolidated statement of operations. See Note 2, Discontinued Oper…
AZN AstraZeneca PLC 85% In July 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in China ("AstraZeneca Ch…
AZN AstraZeneca PLC 85% Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: In July 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with…

Kyntra Bio, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
KYNB-DEBT Debt stack $19.2M 90% Market cache reports total debt of $19.2M.
KYNB-DEBT-10597 Xbrl Convertible 90% xbrl convertible detail from xbrl 2015-12-31.

Kyntra Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kyntra Bio, Inc..

Kyntra Bio, Inc. Ownership

HolderNameConfidenceEvidence
KYNB-OWNER-ARMISTICE-CAPITAL-LLC ARMISTICE CAPITAL, LLC 90% 13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 34 tracked holders.

Kyntra Bio, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ARGX argenx SE 100.00 2
SNYNF Sanofi 100.00 2
OLMA Olema Pharmaceuticals, Inc. 100.00 2
APRE Aprea Therapeutics, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
SLN Silence Therapeutics plc 100.00 2
DRTS Alpha Tau Medical Ltd. 100.00 2
TNXP Tonix Pharmaceuticals Holding Corp. 100.00 2
MGNX MacroGenics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
DEO Diageo plc 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
IDYA IDEAYA Biosciences, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
PYXS Pyxis Oncology, Inc. 100.00 2
View KYNB supply chain intel →

Explore the full interactive supply chain map for Kyntra Bio, Inc..

Open KYNB supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map